Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18282729 | 0.72 | DYRK1A (0.41) | DYRK1APIM1DYRK2DYRK1BCDK9 | |
| SCHEMBL22423043 | 0.71 | DYRK1A (0.40) | DYRK1APIM1DYRK2DYRK1BCDK9 | |
| SCHEMBL22423037 | 0.67 | MAPK1 (0.38) | — | |
| SCHEMBL6342720 | 0.67 | PKM (0.34) | DYRK1A | |
| SCHEMBL18291808 | 0.65 | DYRK1A (0.33) | DYRK1APIM1DYRK2DYRK1BCDK9 | |
| SCHEMBL18282757 | 0.64 | DYRK1A (0.33) | DYRK1APIM1DYRK2DYRK1B | |
| SCHEMBL18281321 | 0.62 | DYRK1A (0.38) | DYRK1APIM1DYRK2DYRK1B | |
| SCHEMBL18291865 | 0.62 | DYRK1A (0.32) | DYRK1A | |
| SCHEMBL31582903 | 0.60 | LMNA (0.38) | — | |
| SCHEMBL19494135 | 0.58 | MAPK1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302484-B1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | DYRK1A 831/4885PIM1 2309/4885DYRK2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.